| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Pepsin (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP012 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Pepsin (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP012-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Pepsin (optional) |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP012-05 |
-
|
| Host |
Rabbit |
| Klon |
SP196 |
| Format |
Concentrate |
| Methode |
P |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
Factor XIIIa
|
Zytomed Systems GmbH |
SP196 |
0.5 ml |
Concentrate |
RUO |
506-4962 |
-
|
| Host |
Rabbit |
| Klon |
SP196 |
| Format |
Concentrate |
| Methode |
P |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
Factor XIIIa
|
Zytomed Systems GmbH |
SP196 |
1 ml |
Concentrate |
RUO |
506-4964 |
-
|
| Host |
Mouse |
| Klon |
E980.1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA o Citrate |
| Positivkontrolle |
Dermatofibroma, placenta or skin |
| Verdünnung |
1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Factor XIIIa C-terminus |
| Lokalisation |
Cytoplasmic |
Factor XIIIa
|
Biocare Medical |
E980.1 |
0.1 ml |
Concentrate |
CE/IVD |
CM357AK |
-
|
| Host |
Mouse |
| Klon |
ZM84 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
| Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
1.0 ml |
Concentrate |
CE/IVD |
Z2394ML |
-
|
| Host |
Mouse |
| Klon |
ZM84 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
| Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
7 ml |
Ready-to-use |
CE/IVD |
Z2394MP |
-
|
| Host |
Mouse |
| Klon |
ZM84 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
| Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
0.5 ml |
Concentrate |
CE/IVD |
Z2394MS |
-
|
| Host |
Mouse |
| Klon |
ZM84 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
| Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
0.1 ml |
Concentrate |
CE/IVD |
Z2394MT |
-
|
| Host |
Mouse |
| Klon |
AC-1A1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
1 ml |
Concentrate |
CE/IVD |
MOB321 |
-
|
| Host |
Mouse |
| Klon |
AC-1A1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB321-01 |
-
|
| Host |
Mouse |
| Klon |
AC-1A1 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB321-05 |
-
|
| Host |
Mouse |
| Klon |
AC-1A1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Placenta |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM141 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant protein corresponding to A-subunit of coagulation Factor XIIIa |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR054 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP103 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP103-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP103-05 |
-
|
| Host |
Mouse |
| Klon |
55K-2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hodgkin lymphoma, ovary |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
1 ml |
Concentrate |
CE/IVD |
MOB560 |
-
|
| Host |
Mouse |
| Klon |
55K-2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hodgkin lymphoma, ovary |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB560-01 |
-
|
| Host |
Mouse |
| Klon |
55K-2 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hodgkin lymphoma, ovary |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB560-05 |
-
|
| Host |
Mouse |
| Klon |
55K-2 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hodgkin lymphoma, ovary |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM560 |
-
|
| Host |
Mouse |
| Klon |
55K-2 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Hodgkin lymphoma, ovary |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
25 ml |
Ready-to-use |
CE/IVD |
PDM560-25 |
-
|
| Host |
Mouse |
| Klon |
ZM192 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin's lymphoma or spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Full length recombinant human FSCN1 protein |
| Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
1.0 ml |
Concentrate |
CE/IVD |
Z2446ML |
-
|
| Host |
Mouse |
| Klon |
ZM192 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin's lymphoma or spleen. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Full length recombinant human FSCN1 protein |
| Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
7 ml |
Ready-to-use |
CE/IVD |
Z2446MP |
-
|
| Host |
Mouse |
| Klon |
ZM192 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin's lymphoma or spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Full length recombinant human FSCN1 protein |
| Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
0.5 ml |
Concentrate |
CE/IVD |
Z2446MS |
-
|
| Host |
Mouse |
| Klon |
ZM192 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Hodgkin's lymphoma or spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Full length recombinant human FSCN1 protein |
| Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
0.1 ml |
Concentrate |
CE/IVD |
Z2446MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified by Protein A and peptide affinity chromatography |
| Methode |
EL, WB, P |
| Verdünnung |
5 - 20 µg/ml |
| Isotyp |
Mouse IgG |
| Verdünnung |
Recombinant protein corresponding Ser2-Ile127 from human FABP1, expressed in E. coli. |
Fatty Acid Binding Protein, Liver (FABP1, L-FABP)
|
Zytomed Systems GmbH |
polyclonal |
100 µl (0.2 mg/ml) |
Purified by Protein A and peptide affinity chromatography |
RUO |
206-0404 |
-
|
| Host |
Rabbit |
| Klon |
SP237 |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
P, FL |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Endometrial Adenocarcinoma, Lung Squamous Cell Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the internal region of human FBXW7 protein |
| Lokalisation |
Cytoplasm, nucleus |
FBXW7
|
Zytomed Systems GmbH |
SP237 |
0.5 ml |
Concentrate |
RUO |
506-5372 |
-
|
| Host |
Rabbit |
| Klon |
SP237 |
| Format |
Concentrate |
| Reaktivität |
MS, RT |
| Methode |
P, FL |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Endometrial Adenocarcinoma, Lung Squamous Cell Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the internal region of human FBXW7 protein |
| Lokalisation |
Cytoplasm, nucleus |
FBXW7
|
Zytomed Systems GmbH |
SP237 |
1 ml |
Concentrate |
RUO |
506-5374 |
-
|
| Host |
Mouse |
| Klon |
MC-GF1 |
| Format |
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant |
| Methode |
F, P, EL, WB |
| Vorbehandlung |
- |
| Verdünnung |
1:400 (P) |
| Isotyp |
Mouse IgG2a |
| Verdünnung |
Recombinant human bFGF |
FGFb (Fibroblast Growth Factor, Basic)
|
Zytomed Systems GmbH |
MC-GF1 |
500 µg |
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant |
RUO |
606-0075 |
-
|
| Host |
Sheep |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
IF |
| Verdünnung |
1:10 - 1:100 |
| Isotyp |
Sheep IgG |
| Verdünnung |
Native |
Fibrinogen (Coagulation Factor I) - FITC
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
606-0188 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
Fibrinogen-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F006 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
Fibrinogen-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F006-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
P |
| Verdünnung |
10 µg/mL |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide: Extracellular domain of human FAP alpha conjugated to Keyhole Limpet Hemocyanin |
Fibroblast Activation Protein alpha (FAP alpha)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
606-0182 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Kidney |
| Verdünnung |
--- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Basement Membrane, Connective Tissue |
Fibronectin
|
Diagnostic Biosystems |
polyclonal |
6 ml |
ready-to-use |
CE/IVD |
PDR170 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Kidney |
| Verdünnung |
1:50 - 1:250 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Basement Membrane, Connective Tissue |
Fibronectin
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP013 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Kidney |
| Verdünnung |
1:50 - 1:250 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Basement Membrane, Connective Tissue |
Fibronectin
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP013-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Kidney |
| Verdünnung |
1:50 - 1:250 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Basement Membrane, Connective Tissue |
Fibronectin
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP013-05 |
-
|
| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
1 ml |
Concentrate |
RUO |
Z2498RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
7 ml |
Ready-to-use |
RUO |
Z2498RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
0.5 ml |
Concentrate |
RUO |
Z2498RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR217 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant full-length human FLI1 protein |
| Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
0.1 ml |
Concentrate |
RUO |
Z2498RT-R |
-
|
| Host |
Rabbit |
| Klon |
SP123 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near the N-terminus of mouse FLK-1 protein |
| Lokalisation |
Cell Membrane |
FLK-1 (mouse)
|
Zytomed Systems GmbH |
SP123 |
0.5 ml |
Concentrate |
RUO |
506-4232 |
-
|
| Host |
Rabbit |
| Klon |
SP123 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near the N-terminus of mouse FLK-1 protein |
| Lokalisation |
Cell Membrane |
FLK-1 (mouse)
|
Zytomed Systems GmbH |
SP123 |
1 ml |
Concentrate |
RUO |
506-4234 |
-
|
| Host |
Mouse |
| Klon |
BGN/1210/55 |
| Format |
Purified |
| Methode |
EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Folate binding protein from bovine milk |
Folate Binding Protein
|
Zytomed Systems GmbH |
BGN/1210/55 |
200 µg |
Purified |
RUO |
606-0136 |
-
|
| Host |
Rabbit |
| Klon |
SP88 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Prostate |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide derived from near C-terminus of human FOXA1 protein |
| Lokalisation |
Nuclear in prostate |
FOXA1
|
Zytomed Systems GmbH |
SP88 |
1 ml |
Concentrate |
RUO |
506-3884 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
| Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
506-19060 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
| Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
506-19062 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
BV, CK, DG, FG, MS, RB, RT |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near C-terminus of human FOXP1 |
| Lokalisation |
Nucleus |
FOXP1
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
506-19064 |
-
|